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Orexin A and orexin B are hypothalamic neuropeptides that play critical roles in the reg-
ulation of sleep/wakefulness, as well as in a variety of physiological functions such as
emotion, reward, and energy homeostasis. The actions of orexins are mediated by two
receptors, orexin 1 (OX1R) and orexin 2 (OX2R) receptors. OX1R and OX2R show partly
overlapping but distinct distributions throughout the central nervous system, suggesting
their differential roles.This review presents and discusses the current knowledge concern-
ing the physiological roles of each orexin receptor subtype, focusing on the regulation of
sleep/wakefulness.
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INTRODUCTION
The neuropeptides orexin A and orexin B (also known as hypocre-
tin 1 and hypocretin 2), were originally identified as endogenous
ligands for two orphan G-protein-coupled receptors (Sakurai et al.,
1998). Both orexin A and orexin B are derived from a common
precursor peptide, prepro-orexin. An mRNA encoding the same
precursor peptide of hypocretin 1 (corresponding to orexin A) and
hypocretin 2 (orexin B) was independently identified by de Lecea
et al. (1998) as a hypothalamus-specific transcript.
The actions of orexins are mediated by two receptors, orexin 1
(OX1R) and orexin 2 (OX2R) receptors (also known as HCRTR1
and HCRTR2) (Sakurai et al., 1998). OX1R shows a higher affinity
for orexin A than orexin B by one-order, while OX2R binds orexin
A and orexin B with similar affinities. Both receptors are coupled
to Gq/11 subclass of G proteins and caused strong excitatory effects
on neurons examined thus far (Sakurai and Mieda, 2011). OX2R
has also been reported to couple to Gi/o in a neuronal cell line
when overexpressed (Zhu et al., 2003).
Orexins are produced in a specific population of neurons
(orexin neurons) that are located exclusively in the hypothalamus,
including the lateral hypothalamic area (LHA), perifornical area,
and posterior hypothalamus (PH) (de Lecea et al., 1998; Peyron
et al., 1998; Sakurai et al., 1998; Date et al., 1999; Nambu et al.,
1999). Orexin neurons project in almost all brain areas with espe-
cially dense projections to monoaminergic neurons, which play
important roles in the regulation of sleep/wake states. Orexins
are thought to be a critical regulator of sleep/wake states. Intrac-
erebroventricular (ICV) administration of orexin A and orexin B
increases wakefulness and suppresses both rapid-eye-movement
(REM) sleep and non-REM (NREM) sleep (Hagan et al., 1999).
More importantly, orexin deficiency causes sleep disorder nar-
colepsy in humans and animals (Chemelli et al., 1999; Lin et al.,
1999; Peyron et al., 2000; Thannickal et al., 2000; Hara et al.,
2001). At present, various reports suggest that orexins are involved
not only in the sleep/wake regulation but also in other physio-
logical and behavioral processes such as food intake, emotion,
stress response, and reward via activation of OX1R and OX2R
(Yamanaka et al., 2003; Akiyama et al., 2004; Mieda et al., 2004;
Boutrel et al., 2005; Harris et al., 2005; Sakurai et al., 2005; Narita
et al., 2006; Yoshida et al., 2006). Recent reports revealed that each
orexin receptor has a different function in these processes. Thus,
understanding such a difference is important for understanding
the function of the orexin system.
This review will discuss the physiological roles of the orexin
system in the regulation of sleep/wakefulness, especially focusing
on the functions of each orexin receptor.
DISTRIBUTIONS OF OREXIN RECEPTOR mRNA
According to data obtained by in situ hybridization histochem-
istry, many brain regions have been shown to differentially express
OX1R and OX2R mRNAs (Trivedi et al., 1998; Lu et al., 2000;
Greco and Shiromani, 2001; Marcus et al., 2001). Consistent with
the broad projections of orexin neurons, OX1R and OX2R show
wide distributions within the brain with partly overlapping but
distinct and complementary distributions. For example, OX2R is
expressed in layers 2 and 6 throughout the cerebral cortex, while
OX1R is expressed in layers 5 and 6, except the cingulate cortex
whereOX1R mRNA is found in layer 3. In the ammon’s horn of the
hippocampus, CA1 and CA2 express OX1R, while CA3 expresses
OX2R.
In the arcuate nucleus and paraventricular nucleus of the
hypothalamus, which are involved in the regulation of feeding,
energy homeostasis, autonomic and endocrine systems, OX2R is
almost exclusively observed. Concerning the nuclei implicated
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in sleep/wake regulation, the locus ceruleus (LC), laterodor-
sal tegmental nucleus (LDT), and pedunculopontine tegmental
nucleus (PPT) mainly express OX1R mRNA, while the tubero-
mammillary nucleus (TMN) almost exclusively expresses OX2R
mRNA. The dorsal raphe (DR) and median raphe (MnR) express
both subtypes. These distributions suggest partly overlapping and
partly distinct roles of these two receptors.
Monoaminergic (i.e., histaminergic, noradrenergic, and sero-
tonergic) and cholinergic neurons in these nuclei have been
considered critical for sleep/wakefulness regulation (Pace-Schott
and Hobson, 2002; Zeitzer et al., 2006). Our recent work deter-
mined precise cellular localization of two orexin receptors in these
nuclei (Figure 1) (Mieda et al., 2011). All histaminergic neurons
in the TMN exclusively expressed OX2R, while all noradrener-
gic neurons in the LC exclusively expressed OX1R. In the DR
and MnR, approximately 90% of serotonergic neurons expressed
OX1R and/or OX2R. In addition, many non-serotonergic cells in
the DR/MnR also expressed OX1R or OX2R mRNA. At least some
populations of these cells were likely to be GABAergic, since a
population of Gad1-positive cells also expressed detectable OX1R
or OX2R mRNA. In the LDT and PPT, all cholinergic neurons
expressedOX1R but notOX2R mRNA, while manyOX1R-positive
and/or OX2R-positive non-cholinergic neurons were intermin-
gled with cholinergic neurons in the area. Gad1 mRNA staining
further revealed that OX1R- or OX2R-expressing cells included
both GABAergic and non-GABAergic cells.
Orexin receptors-positive GABAergic neurons in the DR/MnR
and LDT/PPT, which are intermingled with serotonergic and
cholinergic neurons, respectively, are intriguing. Since GABAer-
gic neurons are likely to function as local inhibitory interneurons
and orexin receptors usually cause excitatory effects on neurons,
simultaneous activation of serotonergic/cholinergic neurons with
GABAergic interneurons by orexins within a nucleus may inhibit
serotonergic/cholinergic neurons. Thus, balance of orexinergic
activation between principal neurons and interneurons may be of
importance. This point will be further discussed in a later section.
OREXIN AND MONOAMINERGIC/CHOLINERGIC SYSTEMS
Orexin neurons project almost all brain regions with especially
dense projections being seen in monoaminergic and choliner-
gic nuclei involved in the regulation of sleep/wakefulness. Various
reports suggested that orexin excites these neurons directly and/or
indirectly in vivo and in vitro (Figure 1). This orexinergic regula-
tion may be important to control sleep/wakefulness. Here, we will
review in vitro and in vivo electrophysiological studies of orexin
receptors in monoaminergic and cholinergic neurons.
SEROTONERGIC NEURONS OF THE DORSAL RAPHE
In 2001, Brown et al. reported that orexin A strongly excited DR
serotonergic neurons in brain slices of rats under the whole-cell
patch clamp recording. The depolarization persisted in the pres-
ence of the voltage dependent Na+ channel blocker, tetrodotoxin,
FIGURE 1 | Schematic illustration of presumed pathways underlying
orexin actions on NREM and REM sleep (Mieda et al., 2011). Orexins
activate histaminergic (His)/GABAergic (GA), serotonergic (5HT),
noradrenergic (NA), and cholinergic (ACh) neurons as well as GABAergic
putative interneurons in wake-promoting nuclei, including the TMN,
DR/MnR, LDT/PPT, and LC. These neurons differentially express OX1R
and/or OX2R, and regulate wakefulness/NREM sleep and NREM/REM
sleep transitions. OX1R and OX2R may be expressed in the same
populations of GABAergic neurons, as shown in the figure, or may be
expressed in distinct populations of these neurons in each area.
Wake/REM-on cholinergic neurons (ACh/W) are likely to suppress NREM
sleep, but REM-on cholinergic neurons (ACh/R), are likely to induce REM
sleep. Wake-active serotonergic and noradrenergic neurons in the DR/MnR
and LC, respectively, counteract activation of REM-on cholinergic neurons
in the LDT/PPT, as well as REM-on neurons in the brainstem reticular
formation (Pace-Schott and Hobson, 2002; Sakurai, 2007). Previous reports
have suggested contributions of GABAergic interneurons inhibiting PPT
cholinergic and raphe serotonergic neurons (Liu et al., 2002; Takakusaki
et al., 2005). LHA, lateral hypothalamic area; PH, posterior hypothalamus.
Reproduced from Sakurai and Mieda (2011) with permission.
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indicating a direct postsynaptic action on the serotonin cells
(Brown et al., 2001). Moreover, orexin A and orexin B induced
inward currents with similar amplitude and dose-dependency
in most serotonergic neurons (Brown et al., 2001; Liu et al.,
2002; Soffin et al., 2004) via activation of Na+/K+ non-selective
cation channels (Liu et al., 2002). These results may suggest that
OX2R is mainly involved in the activation of serotonergic neurons,
although single-cell PCR, in situ hybridization, and immunohisto-
chemical studies revealed that serotonergic neurons express both
OX1R and OX2R (Brown et al., 2001; Liu et al., 2002; Wang et al.,
2005; Mieda et al., 2011).
A recent report revealed that orexin A depolarized DR neu-
rons by activating a noisy inward current (Kohlmeier et al., 2004,
2008). This current was through non-selective cation channels
that did not contribute to the somatic Ca2+ influx. These reports
suggested that orexin A has two independent actions: activation
of non-selective cation channels and activation of a protein kinase
C-dependent enhancement of Ca2+ transients mediated by L-type
Ca2+ channels.
At higher concentrations, orexin also increased spontaneous
inhibitory postsynaptic currents in serotonergic neurons indicat-
ing orexin excited GABAergic interneurons that project to sero-
tonergic neurons in the DR (Liu et al., 2002). Such a structure of
intra-DR circuit may execute a negative feedforward regulation of
the activation of serotonergic neurons by orexin neurons.
Regulation of DR neurons by orexin seems to be even more
complex. Haj-Dahmane and Shen found that orexin B depresses
the evoked glutamate-mediated synaptic currents in DR sero-
tonergic neurons. This effect was mediated by retrograde endo-
cannabinoid release, which depended on the stimulation of post-
synaptic orexin receptors and subsequent activation of phospho-
lipase C and DAG lipase enzymatic pathways but not on a rise
in postsynaptic intracellular calcium (Haj-Dahmane and Shen,
2005).
In vivo extracellular recording also revealed that application
of orexin A increased firing frequency of serotonergic DR neu-
rons in unanesthetized rats during REM sleep or slow-wave sleep,
while during wakefulness, a similar amount of orexin A did not
increase the firing rate (Takahashi et al., 2005). These reports sug-
gest that orexin excited DR serotonergic neurons in a behavioral
state-dependent manner.
NORADRENERGIC SYSTEM
Orexin A and orexin B increased the firing frequency of all LC
neurons in the presence of tetrodotoxin in rat brain slices by intra-
cellular recording (Horvath et al., 1999; Soffin et al., 2002). The
effects of orexin A are fivefold more potent than orexin B. More-
over, the effect was inhibited by selective orexin 1 receptor antag-
onist, SB-334867 (Soffin et al., 2002, 2004). These data suggest
that orexins directly excited LC noradrenergic neurons via OX1R,
which is consistent with exclusive expression ofOX1R in these neu-
rons demonstrated by in situ hybridization (Mieda et al., 2011).
The orexin-induced depolarization of LC noradrenergic neurons
may be produced by augmentation of the non-selective cationic
conductance and suppression of G-protein-coupled inward recti-
fier (GIRK) channel activity (Hoang et al., 2003; Murai and Akaike,
2005).
In addition to the action of orexins within the LC, orexin
A and B also evoked noradrenaline release in the rat cere-
brocortical slice, suggesting that orexins act on OX1R on the
orexin fibers projecting from the LC in the cerebral cortex
(Hirota et al., 2001). Orexin-evoked noradrenaline release was
time- and concentration-dependent and partially extracellular
Ca2+-dependent (Hirota et al., 2001).
Another report suggested that the orexin modulates LC func-
tions via OX1R by regulating noradrenaline release not only
from the axonal terminals, but also from the somatodendritic
region of LC noradrenergic neurons (Chen et al., 2008). Appli-
cation of orexin alone dose-dependently induced somatoden-
dritic noradrenaline release. Orexin A also potentiated N -methyl-
d-aspartate (NMDA) receptor-mediated somatodendritic nora-
drenaline release from LC neurons, which was blocked by SB-
334867, an OX1R antagonist, or a PKC inhibitor, indicating the
involvement of OX1R and PKC. Orexin A enhanced NMDA-
induced intracellular Ca2+ elevation as well (Chen et al., 2008).
Taken together, activation of OX1R of LC noradrenergic neu-
rons regulates not only noradrenergic input to their targets,
but also noradrenergic communication in the soma and den-
drites.
Excitatory effects of orexin A on LC neurons have been demon-
strated also in vivo by measuring their firing rates (Bourgin et al.,
2000) or noradrenaline release into the hippocampus (Walling
et al., 2004). In addition, local administration of orexin A but
not orexin B in the LC of rats suppressed REM sleep in a dose-
dependent manner and increased wakefulness at the expense of
REM sleep and deep slow-wave sleep (Bourgin et al., 2000).
HISTAMINERGIC SYSTEM
Both patch clamp study using freshly isolated neurons and intra-
cellular recording using brain slices revealed that orexin A and
orexin B directly and dose-dependently depolarized TMN his-
taminergic neurons of rats (Bayer et al., 2001; Eriksson et al.,
2001; Yamanaka et al., 2002). Orexin A and B showed almost
the same potency, indicating that orexin-induced excitation of
histaminergic neurons is mediated via OX2R. Consistent with
electrophysiological data, OX2R was shown to be the principle
subtype of orexin receptors by single-cell RT-PCR study, although
both receptor mRNAs were detected in most tuberomammillary
neurons (Eriksson et al., 2001). Histological studies have demon-
strated that TMN histaminergic neurons express OX2R almost
exclusively (Yamanaka et al., 2002; Mieda et al., 2011).
Orexin-induced depolarization was associated with a small
decrease in input resistance. The mechanisms of depolarization
of histaminergic neurons are likely to be related to the activation
of both the electrogenic Na+/Ca2+ exchanger and Ca2+ current
(Eriksson et al., 2001), as well as suppression of GIRK channels
(Hoang et al., 2003).
On the other hand, a recent in vitro optogenetic study demon-
strated that postsynaptic currents and rapid increase of firing
rates in TMN histaminergic neurons evoked by stimulation of
orexin neurons were mediated by glutamate rather than by orex-
ins (orexin neurons are also glutamatergic) (Schone et al., 2012).
This suggests a possibility that orexin might play as a modulator
of the glutamatergic transmission in these cells.
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In vivo application of orexin A to the TMN increased histamine
release in both the medial preoptic area and the frontal cortex in a
dose-dependent manner (Huang et al., 2001). Moreover, perfusion
of orexin A into the TMN of rats through a microdialysis probe
promptly increased wakefulness, concomitant with a reduction in
REM and NREM sleep (Huang et al., 2001; Yamanaka et al., 2002).
These findings indicate that orexins excite TMN histaminergic
neurons mainly via OX2R and enhance histamine release from the
TMN to maintain wakefulness.
CHOLINERGIC SYSTEM
Laterodorsal tegmental nucleus
Whole-cell recordings revealed that orexin exhibited actions both
presynaptically and postsynaptically on LDT cholinergic neurons,
as well as in non-cholinergic neurons in the same area. Orexin
increased frequency and amplitude of spontaneous EPSCs in these
neurons. Postsynaptically, orexin produced an inward current and
an increase in membrane current noise, which were accompanied
by a conductance increase (Burlet et al., 2002). Being similar to DR
serotonergic neurons, orexin A has two independent actions on
LDT cholinergic neurons: activation of non-selective cation chan-
nels and activation of a protein kinase C-dependent enhancement
of Ca2+ transients mediated by L-type Ca2+ channels (Kohlmeier
et al., 2004, 2008).
In a study of in vivo extracellular recordings of LDT neurons in
rats, the application of orexin A induced long-lasting excitation in
five of seven cholinergic neurons (Takahashi et al., 2002). Further-
more, when orexin A was microinjected in the LDT of cats, time
spent in wakefulness was significantly increased due to an increase
in the duration of wake episodes, and time spent in REM sleep was
significantly reduced due to a decrease in the frequency of active
sleep episodes (Xi et al., 2001).
Pedunculopontine tegmental nucleus
Whole-cell patch clamp recordings revealed that orexin A and
orexin B depolarized PPT cholinergic and non-cholinergic neu-
rons dose-dependently in the presence of tetrodotoxin (Kim et al.,
2009a). Approximately 80% of PPT neurons were depolarized by
orexin A, and 20% of PPT neurons did not respond to orexin A
(Kim et al., 2009b). SB-334867, a selective inhibitor for OX1R, sig-
nificantly suppressed the orexin A-induced depolarization. These
results suggest that orexin depolarized PPT neurons directly
through OX1R. This OX1R-mediated depolarization was caused
by a decrease of K+ conductance and an increase of non-selective
cationic conductance (Kim et al., 2009a). It was also indicated
that it was blocked by D609, a phosphatidylcholine-specific PLC
inhibitor, suggesting that the excitatory effects of orexin on PPT
neurons are mediated by PLC-dependent pathway (Kim et al.,
2009b).
An in vivo study demonstrates that orexin inhibited PPT neu-
rons via GABAergic neurons (Takakusaki et al., 2005). In decer-
ebrated cats, an injection of orexin into the PPT increased the
intensity of electrical stimulation required at the PPT to induce
muscle atonia. The effect of orexin on PPT was abolished by simul-
taneous injection of bicuculline, a GABAA receptor antagonist,
into the PPT. These results suggest that orexin enhances GABAer-
gic effects on presumably cholinergic PPT neurons in vivo to
control postural muscle tone.
Cholinergic neurons in these areas include two functionally
distinct types of neurons. Some are active during wakefulness
and REM sleep (W/REM-on neurons) and others are specifically
active during REM sleep (REM-on neurons) (Pace-Schott and
Hobson, 2002; Sakurai, 2007). The latter population is likely to
play a critical role in REM sleep-related physiological phenom-
ena, including muscle atonia. Orexin A excites both cholinergic
and non-cholinergic neurons of the LDT in slice preparations, as
described previously (Burlet et al., 2002). Furthermore, orexin A
microinjection in the cat LDT increases wakefulness and reduces
REM sleep. In addition, as mentioned previously, GABAergic neu-
rons in the PPT mediate suppression of REM sleep and muscle ato-
nia following local injection of orexin A into this area (Takakusaki
et al., 2005). Consistent with the actions of orexins on both
cholinergic and non-cholinergic neurons, orexin receptors are dif-
ferentially expressed in cholinergic and GABAergic neurons of the
LDT/PPT, shown by a histological study (Mieda et al., 2011). Taken
together, these results indicate that in the LDT/PPT, orexin may
activate W/REM-on cholinergic neurons through OX1R to facili-
tate wakefulness. Simultaneously, orexin might activate GABAer-
gic interneurons to inhibit REM-on cholinergic neurons in these
nuclei (Figure 1).
Basal forebrain
Electrophysiological studies were performed on cultured nucleus
basalis neurons from the basal forebrain and on rat brain slice
(Eggermann et al., 2001; Hoang et al., 2004). In cultured neu-
rons, orexin A induced a depolarization and increased firing
accompanied by a decrease of whole-cell conductance in cholin-
ergic neurons. The mechanism of this neuronal excitation was
shown to be accompanied by inhibition of inward rectifier K+
channel (KirNB) activity (Hoang et al., 2004). In rat brain
slices, orexin has a direct excitatory effect on the cholinergic
neurons of the contiguous basal forebrain (Eggermann et al.,
2001). All cholinergic neurons were excited by orexin A and even
more potently by orexin B. This result suggests that the action
depends on OX2R. Thus, orexins may excite cholinergic neurons
in the basal forebrain via OX2R and contribute to the cortical
activation.
The medial septum-diagonal band of Broca (MSDB), via
its cholinergic and GABAergic projections to the hippocampus,
controls the hippocampal theta rhythm and associated learn-
ing and memory functions. MSDB receives a dense innerva-
tion of orexin neurons, and neurons of the MSDB express very
high levels of OX2R. Septohippocampal cholinergic neurons were
excited by orexin A and B with similar EC50 in a concentration-
dependent manner, mediated via a direct postsynaptic mechanism
(Wu et al., 2004). The orexin effect is likely to be mediated
by inhibition of a K+ current, presumably an inward rectifier,
and activation of the Na+–Ca2+ exchanger. Thus orexin effects
within the septum should increase hippocampal acetylcholine
release and thereby promote hippocampal arousal (Wu et al.,
2004).
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DIFFERENTIAL ROLES OF EACH OREXIN RECEPTOR SUBTYPE
IN THE REGULATION OF SLEEP/WAKEFULNESS
MOLECULAR GENETIC STUDIES
Recent studies have established that the orexin (hypocretin) sys-
tem is one of the most important regulators of sleep/wake states
and that its deficiency results in the human sleep disorder nar-
colepsy (Zeitzer et al., 2006; Sakurai and Mieda, 2011). Narcolepsy
is characterized by excessive daytime sleepiness that often results in
“sleep attacks” (sudden onset of NREM sleep), cataplexy (sudden
bilateral skeletal muscle weakening triggered by emotions with-
out loss of consciousness), hypnagogic hallucinations, and sleep
paralysis. These symptoms can be divided into two independent
pathological phenomena. One is the inability to maintain a con-
solidated awake period characterized by abrupt transitions from
wakefulness to NREM sleep (i.e., dysregulation of NREM sleep
onset). This phenomenon manifests clinically as excessive day-
time sleepiness or sleep attacks. The other key phenomenon is
the pathological intrusion of REM sleep into wakefulness or at
sleep onset (i.e., dysregulation of REM sleep onset). It is dur-
ing these periods that patients experience cataplexy, hypnagogic
hallucinations, and sleep paralysis.
Mice with targeted deletion of the prepro-orexin gene
(orexin−/− mice) display a phenotype strikingly similar to nar-
colepsy: abrupt behavioral arrests with muscle atonia (cataplexy),
fragmented wakefulness (inability to maintain consolidated wake-
fulness episodes), and direct transitions from wakefulness to REM
sleep (Chemelli et al., 1999). In addition, functionally null muta-
tions in the OX2R gene were found in two independent lines of
familial narcoleptic dogs (Lin et al., 1999).
Based on studies on orexin receptor-deficient mice (OX1R−/−
and OX2R−/− mice), it has been suggested that deletion of OX1R
produces no measurable effect on sleep/wakefulness states (Saku-
rai, 2007; Hondo et al., 2010). However, OX2R−/− mice have clear
characteristics of narcolepsy, although their behavioral and EEG
phenotype is less severe than that found in orexin−/− mice (Willie
et al., 2003). In infrared videophotographic studies in the dark
phase,OX2R−/−mice showed abrupt behavioral arrests. However,
its frequency was much less than in orexin−/− mice (31-fold lower
frequency in OX2R−/− mice as compared to orexin−/− mice).
Instead, OX2R−/− mice showed a distinct variety of behavioral
arrests with onsets that were more gradual in nature (gradual
arrests). Moreover, orexin−/− mice also exhibit gradual arrests
with a frequency similar to OX2R−/− mice in addition to plenty
of abrupt arrests.
In contrast to abrupt arrests, gradual arrests typically began
during quiet wakefulness and could be easily distinguished from
the normal onset of resting behavior by (i) the absence of stereo-
typic preparation for sleep (e.g., nesting and/or assumption of a
curled or hunched posture with limbs drawn under the body) and
(ii) a characteristic ratchet-like“nodding”of the head over a period
of several seconds with a transition to a collapsed posture (Willie
et al., 2003).
Detailed observations of behaviors during EEG/EMG record-
ings found that abrupt arrests in orexin−/− and OX2R−/− mice
occurred during direct transitions from wakefulness to REM sleep,
whereas EEG/EMG correlates of gradual arrests in both orexin−/−
and OX2R−/− mice invariably revealed the onset of attenuated
muscle tone, but not atonia, and an EEG transition from wakeful-
ness to NREM sleep (Chemelli et al., 1999; Willie et al., 2003). Phar-
macologically, abrupt arrests in orexin−/−mice were suppressed by
systemic administration of clomipramine, an anticataplectic agent
used for treatment of human narcolepsy. Whereas, administration
of caffeine, a psychostimulant used to treat excessive sleepiness
in human narcolepsy, tended to produce a mild exacerbation
of abrupt arrest frequency. In clear contrast, systemic adminis-
tration of caffeine dose-dependently suppressed gradual arrests,
while administration of an anticataplectic agent clomipramine
did not affect the frequency of gradual arrests in both orexin−/−
and OX2R−/− mice. These observations showed strong similarity
with those observed in human narcolepsy patients; psychostimu-
lant drugs are effective for the sleepiness, but exacerbate cataplexy,
which is treatable with antidepressants. This detailed character-
ization of behavioral, pharmacological, and electrophysiological
features of orexin−/− andOX2R−/−mice defined abrupt and grad-
ual arrests as the presumptive mouse correlates of cataplexy and
sleep attack in human narcolepsy, respectively.
In addition to the gradual behavioral arrests, OX2R−/− mice
exhibit fragmentation of wakefulness, another sign of sleepiness,
to the extent similar to that in orexin−/− mice (Willie et al., 2003).
OX1R−/−;OX2R−/−mice appear to have the same phenotype with
orexin−/− mice, implying that these two receptors are sufficient to
mediate regulation of sleep/wakefulness by orexins (Sakurai, 2007;
Hondo et al., 2010). These results of mouse reverse genetic studies
suggest that normal regulation of wake/NREM sleep transitions
depends critically on OX2R activation, whereas the profound dys-
regulation of REM sleep control are unique to narcolepsy from loss
of signaling through both OX1R- and OX2R-dependent pathways.
Substantially lower frequency of cataplexy in OX2R−/− mice
as compared to orexin−/− mice appears to be inconsistent with
the fact that mutations of OX2R gene are solely responsible for
an inherited canine model of narcolepsy, which demonstrate fre-
quent occurrence of cataplexy as well as excessive sleepiness (Lin
et al., 1999). This may result from species difference (e.g., the pre-
cise expression patterns of two orexin receptors). However, even
in dogs, the absence of orexin peptides may cause severe narcolep-
tic symptoms as compared to OX2R mutation. Early studies of
narcoleptic Dobermans and Labradors found these dogs to be 30-
to 80-fold less severely affected with cataplexy than poodles with
sporadic narcolepsy that showed literally hundreds of attacks a
day (Baker et al., 1982), an effect previously attributed solely to
differences in breed and breed size.
As an experiment complementary to the behavioral studies and
baseline sleep/wakefulness recordings of OX1R−/− and OX2R−/−
mice, we elucidated that two orexin receptors play distinct and
differential roles in the regulation of sleep and wakefulness states
by comparing the effects of ICV orexin A administration in
wild-type, OX1R−/− and OX2R−/− mice (Mieda et al., 2011).
The effects of orexin A on wakefulness and NREM sleep were
significantly attenuated in both knockout mice as compared to
wild-type mice, with substantially larger attenuation in OX2R−/−
mice than in OX1R−/− mice. These results suggest that although
the OX2R-mediated pathway has a pivotal role in the promotion
www.frontiersin.org May 2013 | Volume 4 | Article 57 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mieda et al. Sleep/wake regulation by orexin receptors
of wakefulness, OX1R also plays additional roles in promoting
arousal.
In contrast, suppression of REM sleep by orexin A adminis-
tration was slightly and similarly attenuated in both OX1R−/−
and OX2R−/− mice, suggesting a comparable contribution of the
two receptors to REM sleep suppression (Mieda et al., 2011). In
addition, our observations further suggest that orexin A directly
suppresses transitions from NREM sleep to REM sleep, and that
activation of OX1R is sufficient for this effect. Supplementary role
of OX1R in the suppression of NREM sleep is consistent with
the fact that OX2R−/− mice on a C57BL/6J genetic background
show less fragmented wakefulness when compared to orexin−/−
mice and OX1R−/−; OX2R−/− mice (but show similarly frag-
mented wakefulness on a C57BL/6J-129/SvEv mixed background)
(Sakurai, 2007; Mochizuki et al., 2011), suggesting that OX1R is
indispensable for the maintenance of wakefulness in the absence
of OX2R.
Although application of exogenous orexins has been shown to
excite many types of neurons (Sakurai and Mieda, 2011), neurons
directly downstream to orexin neurons in physiological conditions
(i.e., neurons influenced by endogenous orexins that mediate their
wake-promoting and REM-suppressing effects), have remained
uncertain. Several reports suggested that histaminergic neurons in
the TMN play an important role in the arousal-promoting effect
of orexin, supported by the facts that the effect of ICV orexin A
administration is markedly attenuated by the histamine H1 recep-
tor antagonist pyrilamine (Yamanaka et al., 2002) and is absent
in H1 histamine receptor knockout mice (Huang et al., 2001) and
that the TMN expresses OX2R abundantly (Marcus et al., 2001;
Mieda et al., 2011), the subtype whose absence causes narcolep-
tic phenotype in mice and dogs (Lin et al., 1999; Willie et al.,
2003). Mochizuki et al. (2011) produced a mouse model in which
a loxP-flanked gene cassette disrupts production of the OX2R,
but normal OX2R expression can be restored by Cre recombinase.
They showed that targeted Cre expression (i.e., focal restoration of
OX2R expression), in the TMN and adjacent regions rescues frag-
mentation of wakefulness in this mouse model, suggesting that
the orexin signaling mediated by OX2R in the TMN (and possibly
its surrounding area in the PH) is sufficient to prevent sleepiness
caused by systemic OX2R deficiency.
On the other hand, this hypothesis is still controversial. Mice
lacking both OX1R and histamine H1 receptors demonstrate no
abnormality in sleep/wakefulness (Hondo et al., 2010). In addition,
a recent optogenetic study showed that orexin-mediated sleep-
to-wake transitions do not depend on the TMN histaminergic
neurons (Carter et al., 2009). Rather, another optogenetic study
suggested the role of LC noradrenergic neurons as a direct down-
stream pathway of orexin neurons by demonstrating that opto-
genetic inhibition of LC noradrenergic neurons blocked arousal
effects of optogenetic stimulation of orexin neurons (Carter et al.,
2012).
PHARMACOLOGICAL STUDIES
Antagonists for orexin receptors are drawing people’s attention
as novel medications for insomnia (Scammell and Winrow, 2011;
Mieda and Sakurai, 2013). Several non-selective (dual) antago-
nists for orexin receptors, as well as subtype-selective antago-
nists, have been developed. These drugs are indeed useful also
for studying the roles of each subtype in the regulation of
sleep/wakefulness without considering any chronic compensatory
changes that might complicate the phenotypes of genetically
engineered models.
A study reported that an OX2R-selective antagonist
JNJ10397049 has a better ability to promote NREM sleep than
the dual antagonist almorexant in rats (Dugovic et al., 2009).
They suggested that simultaneous inhibition of OX1R attenuates
the sleep-promoting effects mediated by selective OX2R blockade,
possibly correlated with dopaminergic neurotransmission. In con-
trast, another recent study led to a different conclusion (Morairty
et al., 2012). It reported that an OX1R-selective antagonist SB-
334867 produces small increases in REM and NREM sleep, and an
OX2R-selective antagonist EMPA produces a significant increase in
NREM sleep. But administration of almorexant increases NREM
sleep more than these subtype-selective antagonists, leading to the
conclusion that dual orexin receptor antagonism is more effec-
tive for sleep promotion than subtype-selective antagonism. The
difference in these drugs’ capabilities of crossing the blood-brain
barrier, as well as their pharmacokinetic/pharmacodynamic char-
acters, might influence the effectiveness. The latter view is also
consistent with the conclusion derived from studies using subtype-
specific knockout mice that OX2R plays a pivotal role, but OX1R
has additional effects on promotion of wakefulness (Sakurai, 2007;
Mieda et al., 2011).
CONCLUSION
The orexin system is a necessary component for the normal reg-
ulation of sleep/wakefulness. Nevertheless, broad expression of
orexin receptors throughout the brain makes it difficult to identify
neurons and orexin receptor subtypes that are directly regulated
by endogenous orexins and mediate their effects on the physiol-
ogy of interest in a natural context. Future studies using molecular
genetic strategies such as brain region/cell type-specific deletions
and brain region/cell type-specific rescues of orexin receptors,
as well as pharmacological studies of focal administration of
subtype-specific orexin agonists/antagonists, would further dis-
sect the differential roles of orexin receptors in the regulation of
sleep/wakefulness. Furthermore, the orexin system is also impor-
tant for the regulation of a variety of physiological functions,
such as feeding, reward, and emotions. Thus, precise informa-
tion of the different roles of the two orexin receptors is beneficial
not only for understanding the mechanisms underlying orexin-
ergic regulations of physiology, but also for application of orexin
agonists/antagonists as medications for various diseases.
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